Technology Appraisal Committee Meeting (Committee A)

**10 Spring Gardens, London SW1A 2BU**

## Minutes: Confirmed

## Date and Time: Tuesday 25 February 2020, 10am – 2pm

### Present:

1. (Chair) Dr Jane Adam Present for all notes
2. Dr Brian Shine Present for all notes
3. Mr Adrian Griffin Present for notes 1 to 6
4. Khalida Ismail Present for all notes
5. Dr Mark Upton Present for all notes
6. Dr Min Ven Teo Present for all notes
7. Dr Mohit Sharma Present for all notes
8. Ms Pamela Rees Present for all notes
9. Dr Peter Baker Present for all notes
10. Mr Richard Ballerand Present for all notes
11. Dr Rita Faria Present for all notes
12. Dr Roger Whittaker Present for all notes
13. Mr Stephen Sharp Present for notes 1 to 8
14. Dr Steve Edwards Present for all notes
15. Dr Sumithra Maheswaran Present for all notes

### In attendance:

* Helen Knight, Programme Director, NICE, Present for all notes
* Janet Robertson, Associate Director, NICE, Present for all notes
* Thomas Feist, Project Manager, NICE, Present for all notes
* Marcia Miller, Administrator, NICE, Present for all notes
* Sana Khan, Technical Analyst, NICE, Present for notes 1 to 6
* Zoe Charles, Technical Adviser, NICE, Present for notes 1 to 6
* Albany Meikle, Technical Analyst, NICE, Present for notes 7 to 12
* Joanna Richardson, Technical Analyst, NICE, Present for notes 7 to 12
* Sarah Davies, School of Health Related Research (ScHARR), Evidence Review Group, Present for notes 1 to 4
* John Stevens, School of Health Related Research (ScHARR), Evidence Review Group, Present for notes 1 to 4
* Dr Geoff Frampton, Southampton Health Technology Assessments Centre (SHTAC), Evidence Review Group, Present for notes 7 to 9
* Dr Joanna Lord, Southampton Health Technology Assessments Centre (SHTAC), Evidence Review Group, Present for notes 7 to 9
* Dr Graham Collins, Clinical Expert, Consultant Haematologist nominated by Roche, Present for notes 1 to 4
* Dr Peter Irving, Clinical Expert, Consultant Gastroenterologist nominated Janssen, Present for notes 7 to 9
* Dr Richard Pollock, Clinical Expert, Present for notes 7 to 9
* Professor Peter Clark, Cancer Drugs Fund Clinical Lead, Present for notes 1 to 6

### Non-public attendees:

* Rosalee Mason, Corporate Office Coordinator, NICE, Present for all notes
* Adam Storrow, Business Analyst, NICE, Present for all notes
* Ann Greenwood, Editor, NICE, Present for all notes
* Bukky Juwa, PHE Analyst, Present for notes 1 to 4
* Gabrielle Emanuel, PHE Analyst, Present for notes 1 to 4
* Claire Joussot, Project Manager, PHE SACT Partnership, Present for notes 1 to 4

## Notes

### Minutes from the last meeting

1. The committee approved the minutes of the committee meeting held on Tuesday 28 January 2020

## Appraisal of Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) representatives and representatives from Roche.
2. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests.  
   1. Dr Graham Collins declared a direct financial interest as he has received honoraria for advisory and speaker work for Roche.
      1. It was agreed that this declaration would not prevent him from participating in this section of the meeting.
   2. No further conflicts of interest were declared for this appraisal.
3. The Chair introduced the lead team, Dr Roger Whittaker, Mr Adrian Griffith and Pamela Rees gave presentations on the clinical effectiveness and cost effectiveness of Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab.

### Part 2 – Closed session (company representatives, clinical and patient experts, ERG/AG representatives and members of the public were asked to leave the meeting)

1. Agreement on the content of Final Appraisal Determination (FAD) was discussed by the committee.
2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.

## Appraisal of Ustekinumab for treating moderately to severely active ulcerative colitis

### Part 1 – Open session

1. The Vice Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) representatives and representatives from Janssen
2. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests.  
   1. Dr Peter Irving declared an direct financial interest as he has received honoraria for speaking on behalf of or acting in an advisory capacity for Janssen, Pfizer, Roche, Genentech, Abbvie, MSD, Sandoz, Falk, Ferring, Tillots, Arena, Gilead, Takeda, Lilly.
      1. It was agreed that this declaration would not prevent him from participating in this section of the meeting.
   2. Dr Richard Pollock declared a direct non-financial interest as he is the

South London Clinical Research Network specialist Lead for Gastroenterology. Committee member British Society of Gastroenterology IBD section

* + 1. It was agreed that this declaration would prevent him from participating in this section of the meeting.
  1. Mr Adrian Griffins declared a direct financial interest as Janssen, is part of the Johnson & Johnson family of companies and he is employed by Johnson & Johnson.
  2. No further conflicts of interest were declared for this appraisal.

1. The Vice Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators.

### Part 2 – Closed session (company representatives, clinical and patient experts, ERG/AG representatives and members of the public were asked to leave the meeting)

1. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.
2. The committee decision was based on consensus.
3. The committee asked the NICE technical team to prepare a Final Appraisal Determination (FAD) in line with their decisions.

## Next Technology Appraisal (Committee A) Meeting: Thursday 16 April 2020, 10am at NICE, 10 Spring Gardens, London, SW1A 2BU.